Home › NDC Lookup › RxCUI directory › RxCUI 213292

Capecitabine 150 MG Oral Tablet [Xeloda] — RxCUI 213292

RxNorm drug concept · Semantic branded drug
RxCUI 213292 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI213292
Official nameCapecitabine 150 MG Oral Tablet [Xeloda]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asXeloda 150 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)395 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Capecitabine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Taking capecitabine with food helps slow down absorption in a way that's actually built into how your dosing is set up. Studies show that eating a meal before your dose affects how...
  • Why do I need to take capecitabine with food?
  • Hand-and-foot syndrome — also called palmar-plantar erythrodysesthesia — is one of the most common side effects of capecitabine. It causes redness, tenderness, swelling, or peeling...
  • What is hand-and-foot syndrome and what should I do if it happens?
📖 Read our full Capecitabine guide →

🕸️ Concept Web — How Capecitabine 150 MG Oral Tablet [Xeloda] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Capecitabine 150 MG Oral Tablet [Xeloda] RxCUI 213292

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Capecitabine 194000
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xeloda 220961
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Capecitabine Oral Tablet 371250
    • Capecitabine Oral Product 1158877
    • Capecitabine Pill 1158878
    • Capecitabine Oral Tablet [Xeloda] 368280
    • Xeloda Oral Product 1186410
    • Xeloda Pill 1186411
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Capecitabine 150 MG Oral Tablet SCD · 200327
  • Capecitabine 150 MG SCDC · 315557
  • Capecitabine Oral Tablet SCDF · 371250
  • Capecitabine Oral Product SCDG · 1158877
  • Capecitabine Pill SCDG · 1158878

Brand-Name Concepts

  • Capecitabine 150 MG [Xeloda] SBDC · 573202
  • Capecitabine Oral Tablet [Xeloda] SBDF · 368280
  • Xeloda Oral Product SBDG · 1186410
  • Xeloda Pill SBDG · 1186411
  • Xeloda BN · 220961

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 213292 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61269-0475-12 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61269-475-12) XELODA H2-Pharma, LLC 1998-04-30
Observed labelers: H2-Pharma, LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.